


Please type a plus sign (+) inside this box Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	LUD 5501 US
First Inventor	Jean-Christophe Renaud
Title	ASTHMA ASSOCIATED FACTORS AS, etc.
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Applicant claims small entity status
See 37 CFR 1.27.
3. ☒ Specification [Total Pages **46**]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **22**]
5. Oath or Declaration [Total Pages **3**]
 a. ☐ Newly executed (original or copy)
 b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)
6. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Box Patent Application
Commissioner for Patents
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 a. ☐ Computer Readable Form (CRF)
 b. Specification Sequence Listing on:
 i. ☐ CD-ROM or CD-R (2 copies), or ii. ☒ paper
 c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATIONS PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☒ Preliminary Amendment
14. ☐ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i) Applicant must attach form PTO/SB/35 or its equivalent
17. ☒ Other **Verified Statement Claiming Small Entity Status**

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: **09/157,247**Prior application information: Examiner **E. Urban** Group / Art Unit: **1642**

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS☐ Customer Number or Bar Code Labelor ☒ Correspondence address below

Name	FULBRIGHT & JAWORSKI L.L.P. Mary Anne Schofield
------	--

Address	Market Square 801 Pennsylvania Avenue, N.W.
---------	--

City	Washington	State	DC	Zip Code	20004-2615
------	------------	-------	----	----------	------------

Country	US	Telephone	(202) 662-0200	Fax	(202) 662-4643
---------	----	-----------	----------------	-----	----------------

Name (Print/Type)	Mary Anne Schofield	Registration No. (Attorney/Agent)	36,669
-------------------	---------------------	-----------------------------------	--------

Signature	<i>Mary Anne Schofield</i>	Date	February 8, 2002
-----------	----------------------------	------	------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 830.00

Complete if Known

Application Number	Not yet assigned
Filing Date	Concurrently herewith
First Named Inventor	Jean-Christophe Renaud
Examiner Name	N/A
Group Art Unit	N/A
Attorney Docket No.	LUD 5501.1 CON. US

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☐ Deposit AccountDeposit
Account
Number

06-2375

Deposit
Account
Name

Fulbright & Jaworski L.L.P.

The Commissioner is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☐ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee

to the above-identified deposit account.

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	370.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
SUBTOTAL (1)					370.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
25	-20** = 5	9.00	45.00
Independent Claims	8	-3** = 5	42.00
Multiple Dependent			

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
103	18	203	9	Claims in excess of 20	
102	84	202	42	Independent claims in excess of 3	
104	280	204	140	Multiple dependent claim, if not paid	
109	84	209	42	** Reissue independent claims over original patent	
110	18	210	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$ 255.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	460.00
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00

SUBMITTED BY

Name (Print/Type) Mary Anne Schofield

Registration No.
(Attorney/Agent)

36,669

Complete (if applicable)

Telephone (202) 662-4584

Signature

Mary Anne Schofield

Date

February 8, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jean-Christophe Renault

Application No.: Not yet assigned

Group Art Unit: Not yet assigned

Filed: Concurrently herewith

Examiner: Not yet assigned

For: ASTHMA ASSOCIATED FACTORS AS
TARGETS FOR TREATING ATOPIC
ALLERGIES INCLUDING ASTHMA AND
RELATED DISORDERS

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed are the following items for filing in connection with the above-referenced
Design Patent Application:

1. Fee Transmittal
2. Continuation Patent Application Transmittal
3. Petition for three-month extension of time
4. Preliminary Amendment
5. Specification (46 pages) and Figures 1-22 (22 sheets)
6. Declaration
7. Associate Power of Attorney
8. Statement Claiming Small Entity
9. Statement Pursuant to 37 C.F.R. 1.821 (f) and (g)
10. Request to Transfer the CRF (Disk)
11. Sequence Listing
12. Check in the amount of \$830.00 to cover filing fee.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375.

Dated: February 8, 2002

Respectfully submitted,

By Mary Anne Schofield
Mary Anne Schofield
Registration No. 36,669

FULBRIGHT & JAWORSKI L.L.P.
Market Square
801 Pennsylvania Avenue, N.W.
Washington, DC 20004-2604
(202) 662-0200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jean-Christophe Renault

Application No.: Not yet assigned

Group Art Unit: N/A

Filed: Concurrently herewith

Examiner: N/A

For: ASTHMA ASSOCIATED FACTORS AS
TARGETS FOR TREATING ATOPIC
ALLERGIES INCLUDING ASTHMA AND
RELATED DISORDERS

STATEMENT PURSUANT TO 37 CFR 1.821 (f) and (g)

Box Sequence

Commissioner for Patents
Washington, DC 20231


Dear Sir:

The undersigned hereby declares that:

1. I am an attorney registered to practice before the U.S. Patent and Trademark Office. My Registration No. is 36,669.
2. Pursuant to 37 C.F.R. § 1.821(f), the content of the paper copy required by § 1.821(c) is the same as that in the computer readable form required by § 1.821(e), submitted December 17, 1999 in application Serial No. 09/468,433.
3. Pursuant to 37 C.F.R. § 1.821(g), the submitted Sequence Listing in both paper copy form and computer readable form contain no new matter.

Respectfully submitted,

Dated: February 8, 2002

By 
Mary Anne Schofield

Registration No.: 36,669

FULBRIGHT & JAWORSKI L.L.P.
801 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 662-0200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jean-Christophe Renauld

Application No.: Not yet assigned

Group Art Unit: N/A

Filed: Concurrently herewith

Examiner: N/A

For: ASTHMA ASSOCIATED FACTORS AS
TARGETS FOR TREATING ATOPIC
ALLERGIES INCLUDING ASTHMA AND
RELATED DISORDERS

REQUEST TO TRANSFER THE CRF (DISK)


Commissioner for Patents
Washington, DC 20231

Dear Sir:

Applicants submit concurrently herewith a paper copy of a sequence listing reciting the appropriate information in this application, a Statement Under § 1.821 (f) and (g) and a request to have the CRF from the prior application, Serial No. 09/157,247, transferred to this file.

Dated: February 8, 2002

Respectfully submitted,

By 
Mary Anne Schofield
Registration No.: 36,669

FULBRIGHT & JAWORSKI L.L.P.
Market Square
801 Pennsylvania Avenue, N.W.
Washington, DC 20004-2604
(202) 662-4584
Attorneys for Applicant